Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
about
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityNovel strategies to target the ubiquitin proteasome system in multiple myelomaThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingBortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPhase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibRescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitorsNovel therapeutics in multiple myeloma.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaSwitching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.FOXM1 is a therapeutic target for high-risk multiple myeloma.BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibitionThe Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.New proteasome inhibitors in myeloma.Small molecules as pro-apoptotic anticancer agents.Current strategies for treatment of relapsed/refractory multiple myeloma.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.Ixazomib: First Global Approval.Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells.MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinicAdoptive B-cell transfer mouse model of human myelomaRandomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.Proteasome-associated deubiquitinases and cancer.The Proteasome and Myeloma-Associated Bone Disease.A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
P2860
Q26771331-678DDD32-E4C5-42AF-BE52-295780930EC3Q26773246-5BC39A2D-BC53-414B-873F-0AE24D464B0EQ28069789-9C90461A-EC36-4615-8BD9-A09836175B3DQ28082335-C3B8CC8E-7874-4E9F-8B4B-8F837FD3DEEEQ28534703-37FA07CF-7A48-43A8-9640-1586FB7AD905Q30561836-B56E4DBF-7A54-434A-B7C4-D20CFE6A902EQ33415759-0ECED88E-A760-45FD-970F-8C2153820052Q33415893-C450424D-BA0A-414E-B562-2C205C2D2D43Q33418257-BD99EE8F-21EE-4D9C-92AC-BCBCEFD409E0Q33421241-509999AC-871D-48FD-A7C6-1DF06C69E3A5Q33425190-F75E1018-B8A7-41CA-BA9D-7BABCEC6D58CQ34532897-F1CF8DBB-F8F2-4AE0-A952-9C854467CB61Q34637538-8CC0C1BF-8703-481F-8B4C-F3646EE9E5BAQ35260732-523CD887-3653-400A-9ED9-5A0B4EB79963Q35557435-4A757D96-EC87-4BCA-9E9B-292AE0CBACACQ36783627-A76573CF-554F-4ADA-AFF7-6F7C0D3950EBQ37077410-F22DEF95-70F1-4EF4-9119-1B5A16B43D3CQ37348913-3904D798-928F-4A3E-875D-299751F11120Q37737800-A4D8F79A-A3E5-4558-AA2C-80D7B2878ACAQ38052079-EA606BE1-9EA8-4BC3-9125-129186F23D5EQ38162939-F3BACD21-75A2-4CD6-B4C1-BF4C000B6FC3Q38182683-E74C433E-20F5-46A4-8097-3D3DFD9FEBD4Q38202977-5FCF4046-2BA3-42C8-9E65-3BC56CA63A55Q38218209-52828C64-B211-4B3D-845A-E7318227E13BQ38400460-CE42556A-D9BE-4C3D-B7E7-75F693E9D070Q38685108-335BB176-7D89-49E5-BEBE-5D3BA21126CEQ38723292-BB6C6B58-62AB-44BB-9544-D7B765AC1094Q38982736-AE7E0337-E0F3-4B74-BDAC-19F10E4CBF9AQ39101546-678A9634-76FD-4AD8-84AE-F84908CFBD11Q39893133-1377444C-A7EC-4777-8D30-95B132A931D3Q40532419-45CF5A46-69BA-434F-8C42-94FE79DEF9E5Q40770030-CBF12C51-7171-45EE-BCC7-6BDF408B3E0AQ42320787-00488E37-702A-462E-8083-FB17CCBAC6A5Q42818861-B55B88FF-FCAC-47D8-9960-25D912B84A03Q47161331-E662D3BD-1473-480E-8EF7-E1B56E00CB18Q47696279-8E4D757B-964B-4E54-9AAF-4C655C9D8AB3Q47902760-86582453-EF00-40E1-969A-B115D9EEF66DQ50128397-99EFC71E-15D2-4B6F-A2C8-84ECEA3E2BDDQ52716657-45C71175-FAAC-47AA-8A50-DA3D49E04041Q54523381-C3DD43EE-D46F-4E0F-B85B-901271A7B955
P2860
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antitumor activity of the inve ...... and plasma cell malignancies.
@ast
Antitumor activity of the inve ...... and plasma cell malignancies.
@en
type
label
Antitumor activity of the inve ...... and plasma cell malignancies.
@ast
Antitumor activity of the inve ...... and plasma cell malignancies.
@en
prefLabel
Antitumor activity of the inve ...... and plasma cell malignancies.
@ast
Antitumor activity of the inve ...... and plasma cell malignancies.
@en
P2093
P2860
P1476
Antitumor activity of the inve ...... and plasma cell malignancies.
@en
P2093
Allison J Berger
Bret Bannerman
Brian Van Ness
Daniel P Bradley
Edmund C Lee
Erik Kupperman
Jennifer Terkelsen
Jill Donelan
Joseph B Bolen
Kristen Bano
P2860
P304
P356
10.1158/1078-0432.CCR-11-0636
P407
P577
2011-09-08T00:00:00Z